Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.
van Baar ACG, Meiring S, Smeele P, Vriend T, Holleman F, Barlag M, Mostafavi N, Tijssen JGP, Soeters MR, Nieuwdorp M, Bergman JJGHM. van Baar ACG, et al. Among authors: meiring s. Gastrointest Endosc. 2021 Jul;94(1):111-120.e3. doi: 10.1016/j.gie.2020.12.021. Epub 2020 Dec 24. Gastrointest Endosc. 2021. PMID: 33359437 Free article. Clinical Trial.
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.
Meiring S, Meessen ECE, van Baar ACG, Holleman F, Nieuwdorp M, Olde Damink SW, Schaap FG, Vaz FM, Groen AK, Soeters MR, Bergman JJGHM. Meiring S, et al. Am J Physiol Endocrinol Metab. 2022 Feb 1;322(2):E132-E140. doi: 10.1152/ajpendo.00337.2021. Epub 2021 Dec 27. Am J Physiol Endocrinol Metab. 2022. PMID: 34957857 Free PMC article.
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study.
Meiring S, van Baar ACG, Sørensen N, Holleman F, Soeters MR, Nieuwdorp M, Bergman JJGHM. Meiring S, et al. Front Clin Diabetes Healthc. 2022 Jul 5;3:856661. doi: 10.3389/fcdhc.2022.856661. eCollection 2022. Front Clin Diabetes Healthc. 2022. PMID: 36992788 Free PMC article.
Insulin sensitivity and beta cell function after Duodenal Mucosal Resurfacing (DMR): An Open-Label, Mechanistic, Pilot Study.
Busch CBE, Meiring S, van Baar ACG, Gastaldelli A, DeFronzo R, Mingrone G, Hagen M, White K, Rajagopalan H, Nieuwdorp M, Bergman JJGHM. Busch CBE, et al. Among authors: meiring s. Gastrointest Endosc. 2024 Jan 25:S0016-5107(24)00049-X. doi: 10.1016/j.gie.2024.01.031. Online ahead of print. Gastrointest Endosc. 2024. PMID: 38280531 Free article.
Re-Cellularization via Electroporation Therapy of the duodenum combined with GPL-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes; 12 months results of a first-in-human study.
Busch CBE, Meiring S, van Baar ACG, Holleman F, Nieuwdorp M, Bergman JJGHM. Busch CBE, et al. Among authors: meiring s. Gastrointest Endosc. 2024 Apr 29:S0016-5107(24)03163-8. doi: 10.1016/j.gie.2024.04.2904. Online ahead of print. Gastrointest Endosc. 2024. PMID: 38692517
Risk Factors for Severe COVID-19 Among Children and Adolescents Enrolled in Acute Respiratory Infection Sentinel Surveillance in South Africa, 2020-2022.
Bishop K, Meiring S, Tempia S, von Gottberg A, Wolter N, Kleynhans J, Moosa F, du Plessis M, Moyes J, Makhasi M, Chuene B, Samuels AM, Dawood H, Reubenson G, Zar HJ, Quan V, Cohen C, Walaza S. Bishop K, et al. Among authors: meiring s. Influenza Other Respir Viruses. 2024 May;18(5):e13300. doi: 10.1111/irv.13300. Influenza Other Respir Viruses. 2024. PMID: 38666359 Free PMC article.
80 results